On June 5, 2021, the '2021 National Lung Function Academic Conference of the Chinese Medical Association' was held in Shanghai. This academic conference was sponsored by the Chinese Medical Association and its affiliated Respiratory Diseases Branch, and co organized by Zhongshan Hospital affiliated to Fudan University, the First Affiliated Hospital of Guangzhou Medical University, the General Hospital of Tianjin Medical University, the Third Hospital of Peking University, and the Ninth People's Hospital of Shanghai. The purpose of this conference is to better promote new theories, new technologies and new methods related to lung function, improve the level of diagnosis and treatment of lung function related diseases, and supplement the weak points, To achieve the goal of 'standardization' and 'homogeneity' of national pulmonary function technical operation, and to promote the cross integration of this field and the vigorous development of disciplines through academic exchanges, so as to cultivate excellent reserve talents.
The conference invited well-known experts from all over the country to discuss the latest research achievements of pulmonary function discipline in China, providing a high-level, multidisciplinary academic exchange platform for clinical application of pulmonary function examination.
Zhong Nanshan, director of the First Affiliated Hospital of Guangzhou Medical University / national respiratory disease clinical medical research center, CAE Member, and Wang Chen, director of national respiratory medical center / national respiratory disease clinical medical research center, served as honorary chairmen of the conference.
The academic conference held in-depth exchanges on topics such as 'research progress of lung function, grassroots lung function in early screening of chronic respiratory disease, small airway dysfunction and lung function testing, clinical progress of lung function in the treatment of respiratory diseases, lung function and rehabilitation'.
At the meeting, Director Wang Chen had a wonderful sharing on 'Chronic Obstructive Pulmonary Disease in China: Prevalence First, Prevention, Diagnosis, Control and Treatment Healing'.
![王辰主任 王辰主任]()
Nanjing Kuancheng Technology Co., Ltd. (hereinafter referred to as 'Kuancheng Technology') attended the meeting with a solution in the non drug field of lung function rehabilitation, 'Sinasul Salt Sol Therapeutic Apparatus', to listen to and learn from medical experts on the prevention, pathogenesis, diagnosis, treatment, epidemiology and basic aspects of respiratory diseases, including respiratory infections, tumors, chronic obstructive pulmonary diseases A wonderful academic speech on the new progress of clinical and basic medicine in asthma, etc.
![宽诚科技 宽诚科技]()
Professor Zhou Linfu from the Department of Respiratory Medicine of Jiangsu Provincial People's Hospital, in his keynote speech 'The application of lung function in the rehabilitation of chronic obstructive pulmonary disease in stable period', especially introduced the research progress of 'salt aerosol therapy' in the rehabilitation treatment of COPD patients. It is pointed out that salt therapy has a positive effect on improving the lung function index of COPD patients, reducing the number of acute attacks and reducing the use of hormone drugs. The application prospect and scientific research value of this non drug therapy in the field of respiratory rehabilitation are worth looking forward to!
![盐溶胶治疗仪 盐溶胶治疗仪]()
Pulmonary function is one of the most important examination items for clinical diagnosis, severity evaluation and efficacy evaluation of respiratory diseases, and also the gold standard for diagnosis of chronic airway diseases such as COPD and bronchial asthma. The Xinasou Salsol Therapeutic Apparatus of Kuancheng Technology is currently conducting a clinical trial of rehabilitation treatment for COPD in the stable period. The subjects tested their lung function three months after using the Xinasou Salsol Therapeutic Apparatus. The results showed that the key indicators of lung function, such as FVC, FEV1, PEF, MEF, were significantly improved compared with those before use. The follow-up of patients also generally reflected that their breathing, sleep, sputum excretion and other signs had been significantly improved.
The meeting fully demonstrated the latest research progress in the field of pulmonary function in China, promoted the construction of pulmonary function theory and the development of professional technology, and promoted the exchange and cooperation of pulmonary function academia. Kuancheng Technology has also strengthened its responsibility and driving force in promoting the diagnosis and treatment of chronic respiratory diseases and the rehabilitation of lung function in China.